期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 140, 期 2, 页码 369-376出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2017.06.005
关键词
Atopic dermatitis; chronic spontaneous urticaria; biologics; microbiome; biomarker; transcriptome
资金
- Grants-in-Aid for Scientific Research [15H05897] Funding Source: KAKEN
This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis with human samples revealed different immune profiles between childhood and adult AD. Phase III clinical trials of dupilumab, an anti-IL-4 receptor a antibody, in the treatment of AD have successfully finished, and dupilumab will appear in clinical practice as the first biologic for AD in 2017. In addition, a novel biologic that targets IL-31 shows promising results in a phase II trial. As for the skin microbiome study, novel insights into the mechanisms of microbial dysbiosis, such as colonization of Staphylococcus aureus, a common feature of AD, were proposed. Regarding CSU, autoreactive CD4(+) T cells that react to Fc epsilon RI were discovered, which might contribute to the development of CSU. These findings provide new insights into the pathogenesis of AD and CSU and will lead to more specific and personalized treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据